Related Experiment Video
Updated: Sep 27, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
[Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications]
1Medizinische und Chirurgische Klinik und Poliklinik - Innenstadt, Klinikum der Universität, Ludwig-Maximilians Universität, München. Christian.Folwaczny@medinn.med.uni-muenchen.de
Several observations are compatible with an association between an haemostatic imbalance and the pathogenesis of inflammatory bowel disease. The prothrombotic state in Crohn's disease and ulcerative colitis is probably not simply the cause of an increased susceptibility for thrombembolic complications, but might also reflect an important element of the pathogenetic changes observed in the small vessels of the intestinal wall. However, it is still unclear whether alterations in the coagulation system are the cause or the aftermath of the systemic inflammatory response observed in inflammatory bowel disease. Several recent observations describe therapeutic efficacy of unfractioned or low-molecular weight heparin in patients with active ulcerative colitis and Crohn's disease. Based on these clinical observations new concepts concerning the pathophysiology of inflammatory bowel disease have emerged.
Several observations are compatible with an association between an haemostatic imbalance and the pathogenesis of inflammatory bowel disease. The prothrombotic state in Crohn's disease and ulcerative colitis is probably not simply the cause of an increased susceptibility for thrombembolic complications, but might also reflect an important element of the pathogenetic changes observed in the small vessels of the intestinal wall. However, it is still unclear whether alterations in the coagulation system are the cause or the aftermath of the systemic inflammatory response observed in inflammatory bowel disease. Several recent observations describe therapeutic efficacy of unfractioned or low-molecular weight heparin in patients with active ulcerative colitis and Crohn's disease. Based on these clinical observations new concepts concerning the pathophysiology of inflammatory bowel disease have emerged.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease I: Introduction
